Eicosanoids in cirrhosis and portal hypertension

Prostaglandins and Other Lipid Mediators

Volumn 72, Issue 1-2, 2003, Pages 3-18

  Birney, Yvonne ^a   Redmond, Eileen M ^b   Sitzmann, James V ^b   Cahill, Paul A ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

AA; acetylcholine; ACh; adenosine 5 diphosphate; adenosine 5 triphosphate; ADP; arachidonic acid; ATP; BK; bradykinin; Cox; cyclic 3 5 adenosine monophosphate; cyclic AMP; cyclooxygenase; CYP450; cytochrome P450; EC

Indexed keywords

ACETYLCHOLINE; ARACHIDONIC ACID DERIVATIVE; BRADYKININ; ENDOTHELIN; ISOPROSTANE DERIVATIVE; LEUKOTRIENE DERIVATIVE; NITRIC OXIDE; NORADRENALIN; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROTEIN DERIVATIVE; PURINE DERIVATIVE; SEROTONIN DERIVATIVE; VASOACTIVE AGENT; ICOSANOID; LEUKOTRIENE; PROSTACYCLIN DERIVATIVE;

CELL INTERACTION; CHOLESTASIS; CLINICAL FEATURE; CYTOKINE PRODUCTION; DERIVATIZATION; DISEASE COURSE; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMICS; HORMONAL REGULATION; HUMAN; KUPFFER CELL; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER DISEASE; MOLECULAR INTERACTION; MOLECULAR MECHANICS; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PORTAL HYPERTENSION; REVIEW; STELLATE CELL; ANIMAL; FIBROSIS; METABOLISM; PATHOLOGY; PERIPHERAL VASCULAR DISEASE;

ANIMALS; EICOSANOIDS; FIBROSIS; HUMANS; HYPERTENSION, PORTAL; LEUKOTRIENES; PERIPHERAL VASCULAR DISEASES; PROSTAGLANDINS I;

EID: 3042599170     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-8823(03)00080-7     Document Type: Article

References (97)

1. Sikuler E., Kravetz D., Groszmann R.J. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am. J. Physiol. 248:1985;G618-G625
2. Sikuler E., Groszmann R.J. Hemodynamic studies in long- and short-term portal hypertensive rats: the relationship to systemic glucagon levels. Hepatology. 6:1986;414-418
3. Geraghty J.G., Anderson W.J., Carter D.C. Portal venous pressure, and portosystemic shunt in experimental portal hypertension. Am. J. Physiol. 257:1989;652-657
4. Benoit J.N., Womack W.A., Hernandez L., Granger D.N. "Forward" and "backward" flow mechanisms of portal hypertension: relative contributions in the rat model of portal vein stenosis. Gastroenterology. 89:1985;1092-1096
5. Lebrec D., Moreau R. Pathophysiology of portal hypertension. Hepatogastroenterology. 46:(Suppl. 2):1999;1426-1428
6. Kitano S., Dolgor B. Does portal hypertension contribute to the pathogenesis of gastric ulcer associated with liver cirrhosis? J. Gastroenterol. 35:2000;79-86
7. Marnett L.J., Rowlinson S.W., Goodwin D.C., Kalgutkar A.S., Lanzo C.A., et al. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem. 274:1999;22903-22906
8. Grabowski E.F., Weksler B.B., Jaffe E.A. Prostacyclin production by cultured endothelial cell monolayers exposed to step increases in shear stress. J. Lab. Clin. Med. 105:1985;36-43
9. 2, and C in pig aortic endothelial cells synthesizing prostacyclin. J. Biol. Chem. 257:1982;7151-7154
10. Topper J.N., Cai J., Falb D., Gimbrone M.A. Jr. Identification of vascular endothelialgenes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10417-10422
11. Topper J.N., Gimbrone M.A. Jr. Blood flow and vascular gene expression: fluid shear stress as a modulator of endothelial phenotype. Mol. Med. Today. 5:1999;40-46
12. Stoltz J.F., Boisseau M., Muller S. Hemorheology and vascular endothelial cells. J. Mal. Vasc. 24:1999;99-109
13. Groszmann R.J. Nitric oxide and hemodynamic impairment. Digestion. 59:(Suppl. 2):1998;6-7
14. 2) levels in peripheral venous, arterial and portal venous blood in cirrhotic patients with portal hypertension and their clinical implication. Chung Hua Wai Ko Tsa Chih. 33:1995;563-565
15. Ohta M., Kishihara F., Hashizume M., et al. Increased prostacyclin content in gastric mucosa of cirrhotic patients with portal hypertensive gastropathy. Prostaglandins Leukot. Essent. Fatty Acids. 53:(1):1995;41-45
16. Sitzmann J.V., Campbell K., Wu Y., St. Clair C. Prostacyclin production in acute, chronic, and long-term experimental portal hypertension. Surgery. 115:1994;290-294
17. Jeremy J.Y., Mikhailidis D.P., Karatapanis S., et al. Altered prostacyclin synthesis by aortae from hepatic portal vein-constricted rats: evidence for effects on protein kinase C and calcium. J. Hepatol. 21:1994;1017-1022
18. Hou M.C., Cahill P.A., Zhang S. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology. 27:1998;20-27
19. Tsugawa K., Hashizume M., Migou S., et al. A selective cyclo-oxygenase-2 inhibitor, NS-398, may improve portal hypertension without inducing gastric mucosal injury. J. Gastroenterol. Hepatol. 14:1999;642-651
20. Munoz J., Albillos A., Perez-Paramo M., Rossi I., Alvarez-Mon M. Factors mediating the hemodynamic effects of tumor necrosis factor-α in portal hypertensive rats. Am. J. Physiol. 276:1999;G687-G693
21. Burnstock G. Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. J. Anat. 194:1999;335-342
22. Fleming I., Bauersachs J., Busse R. Paracrine functions of the coronary vascular endothelium. Mol. Cell. Biochem. 157:1996;137-145
23. Arnal J.F., Dinh-Xuan A.T., Pueyo M., Darblade B., Rami J. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell. Mol. Life Sci. 55:1999;1078-1087
24. Cines D.B., Pollak E.S., Buck C.A., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 91:1998;3527-3561
25. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997;20(Suppl 2):II-3-10.
26. Forstermann U. Phospholipid metabolism and EDRF production. In: Ryann U, Rubanyi GM, editors. Endothelial regulation of vascular tone. New York: Marcel Decker; 1992. p. 121-36.
27. Luckoff A., Pohl U., Mulsch A., Busse R. Differential role of extracellular and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells. Br. J. Pharmacol. 95:1998;189-196
28. 4 induced formation of inositol phosphate and prostacyclin in human umbilical vein endothelial cells. J. Cell. Physiol. 177:1998;103-108
29. 2 production by G proteins in bovine aortic endothelial cells. Am. J. Physiol. 271:1996;C555-C562
30. 2 purinoceptor stimulation of endothelial prostacyclin production. Biochem. J. 320:1996;221-226
31. Guarner C., Soriano G. Prostaglandin and portal hypertension. Prostaglandins Leukot. Essent. Fatty Acids. 48:1993;203-206
32. Fernandez M., Garcia-Pagan J.C., Casadevall M., et al. Acute, and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis. Gastroenterology. 110:1996;1529-1535
33. Wu Y., Burns R.C., Sitzmann J.V. Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension. Hepatology. 18:1993;1416-1421
34. Oberti F., Sogni P., Cailmail S., et al. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. Hepatology. 18:1993;621-627
35. Chan C.C., Lee F.Y., Wang S.S., et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology. 30:1999;630-635
36. Lin P.W., Shan Y.S. Portal hemodynamics and humoral factors involved in a portal hypertensive rabbit model. Proc. Natl. Sci. Counc. Repub. China B. 19:(4):1995;240-245
37. 1 alpha in the course of liver cirrhosis. Prostaglandins. 53:(1):1997;11-20
38. Roberts R., Kamath P.S. Gastrointestinal lesions in liver cirrhosis. Mayo Clin. Proc. 71:(9):1996;874-881
39. Ferraz J.G., Wallace J.L. Underlying mechanisms of portal hypertensive gastropathy. J. Clin. Gastroenterol. 25:(Suppl. 1):1997;S73-S78
40. Fujiwara Y., Arakawa T., Higuchi K., Kuroki T. Ascites and hepatorenal syndrome: pathophysiology and management. Nippon Rinsho. 56:(9):1998;2387-2390
41. Beck P.L., McKnight W., Lee S.S., Wallace J.L. Prostaglandin modulation of the gastric vasculature and mucosal integrity in cirrhotic rats. Am. J. Physiol. 265:(3 Pt 1):1993;G453-G458
42. Moore K. Cytochrome P450 products and renal function in cirrhosis: the HETE is on. Hepatology. 27:(4):1998;1166-1168
43. Sacerdoti D., Balazy M., Angeli P., Gatta A., McGiff J.C. Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J. Clin. Invest. 100:(5):1997;1264-1270
44. Sacerdoti D., Bolognesi M., Gatta A., McGiff J.C., Oyekan A. CYP450-dependent epoxyeicosatrienoic acids may participate in the pathophysiology of portal hypertension by differentially modulating portal and mesenteric arterial resistance in cirrhotic rats. Hepatology. 30:1999;A307
45. Benoit J.N., Barrowman J.A., Harper S.L., Kvietys P.R., Granger D.N. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am. J. Phys. 247:(5 Pt 1):1984;G486-G493
46. Benoit J.N., Granger D.N. Splanchnic hemodynamics in chronic portal hypertension. Semin. Liver Dis. 6:(4):1986;287-298
47. Javle P., Yates J., Kynaston H.G., Parsons K.F., Jenkins S.A. Hepatosplanchnic hemodynamics and renal blood flow and function in rats with liver failure. Gut. 43:(2):1998;272-279
48. Loginov A.S., Vysotskaia R.A. Prostaglandins in chronic liver diseases. Vestn. Ross. Akad. Med. Nauk. 12:1995;32-38
49. Gatta A., Sacerdoti D., Bolognesi M., Merkel C. Portal hypertension: state of the art. Ital. J. Gastroenter. Hepatol. 31:(4):1999;326-345
50. 2 as the major eicosanoid from liver endothelial and Kupffer cells. Biochim. Biophys. Acta. 959:(2):1988;143-152
51. Fennekohl A., Schieferdecker H.L., Jungermann K., Puschel G.P. Differential expression of prostanoid receptors in hepatocytes, Kupffer cells, sinusoidal endothelial cells and stellate cells of rat liver. J. Hepatol. 30:(1):1999;38-47
52. Shah V., Haddad F.G., Garcia-Cardena G., et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J. Clin. Invest. 100:(11):1997;2923-2930
53. McCuskey R.S., Reilly F.D. Hepatic microvasculature: dynamic structure and its regulation. Semin. Liver Dis. 13:1993;1-11
54. Burt A.D., LeBail B., Balabaud C., Bioulac-Sage P. Morphologic investigation of sinusoidal cells. Semin. Liver Dis. 13:1993;21-37
55. Needleman P., Turk J., Jakschik B.A., Morrison A.R., Lefkowith J.B. Arachidonic acid metabolism. Annu. Rev. Biochem. 55:1986;69
56. Bankey P., Beecherl E., Bibus D., See D., McIntyre K. Liposomes modulate Kupffer cell endotoxin response. Arch. Surg. 130:(12):1995;1266-1272
57. 2, and protein synthesis in lipopolysaccharide-exposed rat Kupffer cells. Eur. J. Biochem. 191:1990;583-589
58. Ayala A., Perrin M.M., Wang P., Chaudry I.H. Sepsis induces an early increased spontaneous release of hepatocellular stimulatory factor (interleukin-6) by Kupffer cells in both endotoxin tolerant and intolerant mice. J. Surg. Res. 52:(6):1992;635-641
59. Tolman K.G. Eicosanoids and the Liver. Prostaglandins and other lipid mediators. 61:2000;163-174
60. 2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem. 263:1988;5380-5384
61. Pruimboom W.M., van Dijk J.A., Tak C.J., et al. Interactions between cytokines and eicosanoids: a study using human peritoneal macrophages. Immunol. Lett. 41:1994;255-260
62. Knudsen P.J., Dinarello C.A., Strom T.B. Prostaglandins post-transcriptionally inhibit monocyte expression of interleukin-1 activity by increasing intracellular cyclic adenosine monophosphate. J. Immunol. 137:1986;3189-3194
63. 2 suppresses tumor necrosis factor but not interleukin-1α or beta-mRNA and cell-associated bioactivity. J. Leukoc. Biol. 45:1989;416-421
64. Williams K.I., Higgs G.A. Eicosanoids and inflammation. J. Pathol. 156:1988;101-110
65. 2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl. Acad. Sci. U.S.A. 93:1996;4885-4890
66. Wanner G.A., Muller P., Ertel W., et al. Differential effect of cyclooxygenase metabolites on proinflammatory cytokine release by Kupffer cells after liver ischaemia and reperfusion. Am. J. Surg. 175:(2):1998;146-151
67. 2 in thioacetamide-induced liver cirrhosis. Exp. Tox. Pathol. 49:(1/2):1997;141-146
68. 1 infusion on the liver circulation. Nippon Geka Gakkai Zasshi. 89:1988;898-905
69. 1 enhances hepatic portal venous flow by dilating the portal vascular bed in 70% hepatectomized dog. Gastroenterologia Japonica. 27:1992;341-347
70. 1 on hepatic blood flow during reperfusion after ischaemia and hepatectomy. Br. J. Surg. 86:(6):1999;776-783
71. 1 in vitro. J. Gastroenterol. Hepatol. 13:1998;S14-S18
72. 1 reduces the production of CXC chemokines in endotoxin-induced rat liver injury. Hepatol. Res. 19:2001;74-84
73. 1 administration during hepatectomy for cirrhotic hepatocellular carcinoma. Hepatogastroenterology. 47:(32):2000;461-464
74. 1 infusion and functional hepatic flow in control subjects and in patients with cirrhosis. Digest. Dis. Sci. 44:(2):1999;377-384
75. 2: differential sensitivity of platelet transduction processes and functional response to inhibition by cyclic AMP. Biochem. J. 232:1985;267-271
76. Davi G., Ferro D., Basili S., et al. Increased thromboxane metabolites excretion in liver cirrhosis. Thrombosis & Haemostasis. 79:(4):1998;747-751
77. Tran-Thi T.A., Gyufko K., Reinke M., Decker K. Output and effects of thromboxane produced by the liver perfused with phorbol myristate acetate. Biol. Chem. Hoppe-Seyler. 369:(10):1988;1179-1184
78. 2 concentration and platelet count in liver diseases. Chung-Hua Nei Ko Tsa Chih Chinese J Intern Med 1992;31(2):80-3, 125.
79. Lemberg A., Calabrese G., Majowicz M. Prostanoid production in endothelial and Kupffer liver cells from monocrotaline intoxicated rats. Hum. Exp. Toxicol. 17:(10):1998;564-569
80. Weintraub N.L., Fang X., Kaduce T.L., et al. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ. Res. 81:(2):1997;258-267
81. Bauer M., Zhang J.X., Bauer I., Clemens M.G. ET-1 induced alterations of hepatic microcirculation: sinusoidal and extrasinusoidal sites of action. Am. J. Phys. 267:(1 Pt 1):1994;G143-G149
82. Zhang J.X., Bauer M., Clemens M.G. Vessel- and target cell-specific actions of endothelin-1 and endothelin-3 in rat liver. Am. J. Physiol. 269:(2 Pt 1):1995;G269-G277
83. Bauer M., Paquette N.C., Zhang J.X., et al. Chronic ethanol consumption increases hepatic sinusoidal contractile response to endothelin-1 in the rat. Hepatology. 22:(5):1995;1565-1576
84. Kawada N., Seki S., Kuroki T., Kaneda K. ROCK inhibitor Y-27632 attenuates stellate cell contraction and portal pressure increase induced by endothelin-1. Biochem. Biophys. Res. Commun. 266:(2):1999;296-300
85. Tanaka Y., Nouchi T., Yamane M., et al. Phenotypic modulation in lipocytes in experimental liver fibrosis. J. Pathol. 164:(3):1991;273-278
86. 2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J. Hepatol. 17:(2):1993;220-226
87. Beckh K., Kneip S., Arnold R. Direct regulation of bile secretion by prostaglandins in perfused rat liver. Hepatology. 19:(5):1994;1208-1213
88. Weidenbach H., Scheibner J., Stange E.F., Adler G., Beckh K. Reduction of bile secretion by prostaglandins in the rat in vivo. Life Sci. 58:(18):1996;1531-1538
89. 1 on canine hepatic bile flow. J. Surg. Res. 18:(4):1975;391-397
90. Quiroga J., Prieto J. Liver cytoprotection by prostaglandins. Pharmacol. Ther. 58:(1):1993;67-91
91. Claria J., Titos E., Jimenez W., et al. Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology. 115:(1):1998;147-156
92. Titos E., Claria J., Bataller R., et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology. 119:(3):2000;794-805
93. 2α, a product of lipid peroxidation, increases portal pressure in normal and cirrhotic rats. Gastroenterology. 112:(1):1997;208-213
94. 2α-III, a marker of lipid peroxidation, do not correlate with increased portal pressure in cirrhotic patients. J. Invest. Med. 46:(9):1998;430-434
95. 2. Pharmacology. 60:(3):2000;155-160
96. 2 receptor in vivo. Circ. Res. 101:(24):2000;2833-2840
97. Thorin E., Shreeve S.M. Heterogeneity of vascular endothelial cells in normal and disease states. Pharmacol. Ther. 78:(3):1998;155-166